Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
21°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Therapeutics, Inc. - Common Stock
(NQ:
ESPR
)
2.150
-0.060 (-2.71%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Therapeutics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stocks That Hit 52-Week Lows On Tuesday
March 14, 2023
Tuesday's morning session saw 84 companies set new 52-week lows.
Via
Benzinga
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
March 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for Esperion Therapeutics
February 27, 2023
Via
Benzinga
Looking Into Esperion Therapeutics's Return On Capital Employed
February 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
March 07, 2023
Via
Benzinga
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
March 07, 2023
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at...
Via
Benzinga
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
March 06, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P...
Via
Benzinga
Esperion Therapeutics's Earnings Outlook
February 20, 2023
Via
Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 06, 2023
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 06, 2023
Via
Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
March 06, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500...
Via
Benzinga
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
March 06, 2023
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose...
Via
Benzinga
Esperion Therapeutics Stock Is Diving: What's Going On?
March 06, 2023
Esperion Therapeutics Inc (NASDAQ: ESPR) shares are trading lower Monday after the company published new data on its treatment aimed at
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
Via
Benzinga
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
March 06, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.
Via
Benzinga
Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors
March 06, 2023
Via
Benzinga
Esperion Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
March 06, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
March 04, 2023
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Launches New Scientific Website
February 24, 2023
Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and More
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
February 23, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
CLEAR Outcomes Company Update Call: Detailed Results Discussion
February 22, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
February 21, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
February 20, 2023
– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint –
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
February 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
January 11, 2023
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
January 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Top Picks For 2023: Esperion
January 02, 2023
Esperion is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid, already FDA approved to reduce LDL cholesterol. Let's take a closer look at why it's a top pick...
Via
Talk Markets
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
December 19, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
